|
Malignant neoplasm of mouth
|
0.340 |
Biomarker
|
group |
BEFREE |
Matrix metalloproteinase 20-dentin sialophosphoprotein interaction in oral cancer.
|
25666817 |
2015 |
|
Malignant neoplasm of mouth
|
0.340 |
Biomarker
|
group |
BEFREE |
DSPP-silencing in OSC2 cell decreased salient hallmarks of oral tumorigenesis and provides the first functional evidence of a potential key role for DSPP in oral cancer biology.
|
21103065 |
2010 |
|
Malignant neoplasm of mouth
|
0.340 |
Biomarker
|
group |
CTD_human |
DSPP-silencing in OSC2 cell decreased salient hallmarks of oral tumorigenesis and provides the first functional evidence of a potential key role for DSPP in oral cancer biology.
|
21103065 |
2010 |
|
Malignant neoplasm of mouth
|
0.340 |
Biomarker
|
group |
BEFREE |
The objective of this study was to determine the effects of DSPP/MMP20 gene silencing on oral cancer stem cell (OCSC) markers.
|
30002682 |
2018 |
|
Malignant neoplasm of mouth
|
0.340 |
Biomarker
|
group |
BEFREE |
Our data indicate that secretome derived from salivary gland cancer cells can influence the expression of two potential biomarkers of oral cancer-namely, bone sialoprotein (BSP) and dentin sialoprotein (DSP)-in normal salivary gland cells.
|
27881474 |
2017 |
|
Mouth Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Dentin sialophosphoprotein (DSPP) gene-silencing inhibits key tumorigenic activities in human oral cancer cell line, OSC2.
|
21103065 |
2010 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
In an effort to clarify the effects of DPP-4 inhibitors (DPP-4is) on diabetes-related renal damage, we performed a narrative review of available clinical trials and other experimental studies focusing on renal effects of DPP-4is.
|
29223646 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Although both DPP-4i and SGLT2i are effective add-on antihyperglycemic therapies to metformin monotherapy, baseline characteristics, such as HbA<sub>1C</sub>, renal function, and age, should be considered when choosing between the 2 classes to allow for optimal and timely diabetes management.
|
29174215 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Our control group included subjects without diabetes (n = 5,582), and our treatment groups with diabetes included DPP-4i users (n = 1,410) and DPP-4i non-users (n = 4,172).
|
31496139 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
PCPs reported they provide referral to DPP and DSME on average to 45% and 67% of their newly diagnosed patients with pre-diabetes and diabetes, respectively.
|
28878936 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings support the application of DPP-4i as a preferred option for treating ulcers in patients with diabetes.
|
29254987 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
DPP-4i did not increase the risk of adverse clinical outcomes in patients with DM and HF.DPP-4i may be beneficial in HFpEF.
|
28592726 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase-4 enzyme metabolizes glucagon-like peptide-1 and various dipeptidyl peptidase-4 enzyme inhibitors (DPP-4i) are also used in the management of diabetes.
|
31425698 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We are now entering the very exciting era of treatment and management of diabetes mellitus (DM) with the emergence of new therapeutic agents, including sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitor (DPP-4i).
|
29541610 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Intervention clinic patients were invited to participate in a face-to-face SDM visit with a pharmacist who used a decision aid (DA) to describe prediabetes and four possible options for diabetes prevention: DPP, DPP ± metformin, metformin only, or usual care.
|
31471729 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
At baseline, patients initiated on SGLT-2i are younger (about 6 years) and more heavy (about 7.5 kg), have higher A1C level (0.5% more), a longer diabetes duration and more CV events (20% more) than patients initiated on DPP-4i.
|
31326454 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, adding another drug to a DPP-4I was related to a younger age and higher BMI.Patients' age, duration of diabetes, obesity, and glycemic control at baseline influenced the choice of hypoglycemic agents.
|
28207538 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Topical treatment with DPP-IVi prevented glial activation, apoptosis and vascular leakage induced by diabetes in db/db mice (p < 0.05).
|
28779212 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
K-DPP is the first well evaluated community-based, peer-led diabetes prevention program in India.
|
29298703 |
2018 |
|
Cardiovascular Diseases
|
0.090 |
Biomarker
|
group |
BEFREE |
The HR of DPP-4i use was also lower than that of SU use in patients without underlying CVD (HR: 0.591; 95% CI: 0.476-0.735) but not in patients with underlying CVD (HR: 0.727; 95% CI: 0.527-1.003).
|
29850606 |
2018 |
|
Cardiovascular Diseases
|
0.090 |
Biomarker
|
group |
BEFREE |
The objective of this nationwide study was to compare the risk of all-cause mortality, fatal and nonfatal cardiovascular disease (CVD), and severe hypoglycemia in patients with type 2 diabetes (T2D) on metformin monotherapy treatment starting second-line treatment with either insulin or dipeptidyl peptidase-4 inhibitor (DPP-4i).
|
28056431 |
2017 |
|
Cardiovascular Diseases
|
0.090 |
GeneticVariation
|
group |
BEFREE |
To examine whether dipeptidyl peptidase 4 inhibitors (DPP-4I) increase acute pancreatitis risk in older patients and whether the association varies by age, sex, and history of cardiovascular disease (CVD).
|
29618573 |
2018 |
|
Cardiovascular Diseases
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Among the patients with underlying CVD, SGLT-2i-treated patients were associated with a lower risk of hHF from 30 days to 3 years after initiating drugs compared with DPP-4i.
|
29935543 |
2018 |
|
Cardiovascular Diseases
|
0.090 |
Biomarker
|
group |
BEFREE |
ADA = American Diabetes Association; DPP = Diabetes Prevention Program; CVD = cardiovascular disease.
|
30289308 |
2018 |